“Cancer experts have extensively discussed combination cancer therapies, emphasizing that cancers often require multiple treatment mechanisms to overcome the adaptive resistance of cancer cells.”
[a:rti]Cure’s All-in-One Multimodal Cancer Gene Therapy Platform for Combination Cancer Therapy
“[a:rti]Cure’s retroviral technology is an ideal platform for multimodal cancer gene therapy because it has potent advantages for gene delivery efficiency, safety, and tolerability
in intravenous administration as well as intratumoral injection.”
"We offer a new gene delivery technology capable of simultaneously delivering multiple cancer therapeutic genes throughout the entire tumor tissue."
[a:rti]Cure is growing into an innovative R&D company that develops and applies next-generation ‘Oncospreading Virus Platforms’ tailored for cancer treatments with new modality combinations.
Overcoming of loss of therapeutic genes during spreading on Tumor
[a:rti]cure's platform technology is a product born from the know-how to solve the problem of therapeutic gene loss due to non-homologous recombination that occurs during retrovirus replication, which was the biggest obstacle in the development of sRRV.
Recombination-free sRRV system
sRRV : semi(or split)-Replicating Retroviral Vector
- The wild-type retroviral genome is split into two separate parts using synthetic biology techniques, allowing the insertion of two or more therapeutic genes for use in a multimodal treatment strategy.
- This innovative sRRV system enables continued viral replication after gene delivery to cancer cells, facilitating the spread to surrounding cancer cells.
[a:rti]Cure’s platform technology offers solutions to the challenges of cancer gene therapy.
sRRV : semi(or split)-Replicating Retroviral Vector
- The wild-type retroviral genome is split into two separate parts using synthetic biology techniques, allowing the insertion of two or more therapeutic genes for use in a multimodal treatment strategy.
- This innovative sRRV system enables continued viral replication after gene delivery to cancer cells, facilitating the spread to surrounding cancer cells.
”[a:rti]Cure's sRRV system is the world's only platform technology that enables multimodal cancer gene therapy."
All-in-One Gene Therapy
All-in-One ”Combination Gene Therapy”
Securing Market Leadership with [a:rti]Cure’s Powerful IP Portfolio
[a:rti]Cure’s Pipeline
Scroll horizontally to view.
| Pipeline | Target/Prevalence |
Discovery  Pre-IND IND Clinical |
|---|---|---|
| Dual Suicide | Recurrent glioma (dual suicide genes) |
 2025: GMP production, GLP Tox Study, IND filing, and Clinical Trial I/IIa: Samsung Medical Center
|
| 100k every year | ||
| Retinoblastoma (dual suicide genes) |
Currently conducting joint research and development with the Pediatric Ophthalmology Department at Seoul National University Hospital
|
|
| 11 cases per million children | ||
| Advanced cancer (MSC-sRRV) |
Indication: Metastatic cancers
|
|
| 10per 100,000 population per year | ||
| Suicide + CAR |
TNBC (suicide + CAR) |
|
| 200k new case per year | ||
| Triple modality platform | melanoma |
Suicide + anti-PD-L1 + shXXX RNA (indication: melanoma) : Triple modality gene therapy
|
| 330k new case per year | ||
| Not disclosed | Autoimmune disease |
 |
Scroll horizontally to view.
"No integration-related toxicity has been observed over more than 25 years in thousands of patients treated with retroviral vectors, whether delivered into tumor cells as defective vectors or as replicating vectors."
First-in-human clinical trials using RRV began in 2010 for the treatment of recurrent high-grade gliomas
2010
Final analysis of the Phase III trial results in late 2019
2019
globally a total of 403 patients enrolled
All clinical trials to date have demonstrated excellent safety profiles, even though they included trials that administered Replicating Retroviral Vectors (RRV) intravenously.
Collins et al., Clinical development of retroviral replicating vector Toca 511 for gene therapy of cancer. Expert Opinion on Biological Therapy 21(9) 1199-1214 (2021)
[a:rti]Cure developed an sRRV platform in which the RRV is divided into two parts.
